| AVEO Achieves Enrollment Target Ahead of Schedule for Pivotal Phase 3 Trial of ... - MarketWatch (press release) |
|
|
MarketWatch (press release)... its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma (RCC). ... read more |